Therapy related acute myeloid leukemia with t(10:16): a rare entity

Hematology Reports

Volumn 3, Issue 3, 2011, Pages 69-71

  Uppal, Guldeep K ^a   Leighton, John ^b   Da Costa, Deline ^b   Czulewicz, Andrew ^b   Palazzo, Irma E ^b  

^a TEMPLE UNIVERSITY HOSPITAL   (United States)

^b TEMPLE UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

Acute myeloid leukemia; Myelodysplastic syndrome

Indexed keywords

EID: 84886084624     PISSN: 20388322     EISSN: 20388330     Source Type: Journal    
DOI: 10.4081/hr.2011.e23     Document Type: Article

References (18)

1. Ricci F, Tedeschi A, Montillo M, Morra E. Therapy related myeloid neoplasms in chronic lymphocytic leukemia and Waldenström’s macroglobulinemia. Mediterr J Hematol Infect Dis 2011;3: e2011031.
2. Vardiman, Thiele J, Arber DA et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
3. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:17507.
4. Yamauchi T, Nowak BJ, Keating MJ, Plunkett W. DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 2001;7:3580-9.
5. Morrison VA, Rai KR, Peterson BL et al. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol 2002;20:387884.
6. Kluk M, Toomey C, Hochberg E, Hasserjian R. Myelodysplastic syndromes following therapy with purine analogues-Therapy related myeloid neoplasms? (Poster Presentation) USCAP annual meeting 2009. Available from: h t t p: / / w w w. a b s t r a c t s 2 v i e w. c o m / uscap09/view.php?nu=USCAP09L_1234
7. Čolović M, Suvajdžić N, Janković G et al.Therapy-related myelodysplastic syndrome and acute myeloid leukemia in patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. Biomed Pharmacoter 2011;65:319-21.
8. Tam CS, O’Brien S, Wierda W et al. Long term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
9. Larson RA, Wang Y, Banerjee M et al. Prevalence of the inactivating 609C-->T polymorphism in the NAD(P) H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood 1999;94:803-7.
10. Carney DA, Seymour JF. Therapy-related myelodysplasia and fludarabine combination therapy-do the benefits justify the risk? Leuk Lymphoma 2010;51:1957-9.
11. Tam CS, Seymour JF, Prince HM et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica 2006;91:1546-50.
12. Vizmanos JL. t(10;16)(q22;p13). Atlas Genet Cytogenet Oncol Haematol. May 2006. Available from: http://atlasgeneticsoncology.org/Anomalies/t1016q22p13ID13 32.html
13. Katsumoto T, Yoshida N, Kitabayashi I. Roles of the histone acetyltransferase monocyticleukemia zinc finger protein in normal and malignant hematopoiesis. Cancer Sci 2008;99:1523-7.
14. Quesnel B, Kantarjian H, Bjergaard JP et al. Therapy-related acute myeloid leukemia with t(8;21), inv(16), and t(8;16): a report on 25 cases and review of the literature. J Clin Oncol 1993;11:2370-9.
15. Pébusque MJ, Lafage M, Lopez M, Mannoni P. Preferential response of acute myeloid leukemias with translocation involving chromosome 17 to human recombinant granulocyte colony-stimulating factor. Blood 1988;72:257-65.
16. Panagopoulos I, Fioretos T, Isaksson M et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum Mol Genet 2001;10:395-404.
17. Vizmanos JL, Larrayoz MJ, Lahortiga I et al. t(10;16)(q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia. Genes Chromosomes Cancer 2003;36:402-5.
18. Kojima K, Kaneda K, Yoshida C et al. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16) (q22;p13). Br J Haematol 2003,120:271-3.